{
    "clinical_study": {
        "@rank": "161538", 
        "arm_group": {
            "arm_group_label": "GB-0998", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "It is intended to examine the safety and efficacy of desensitization therapy by GB-0998\n      (intravenous immunoglobulin) for the anti-donor antibody positive recipient in need of\n      pre-transplant desensitization. Patients with positive FCXM-T after performing twice double\n      filtration plasmapheresis (DFPP) therapy will receive GB-0998 1g/kg/day for four days."
        }, 
        "brief_title": "The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "End Stage Renal Disease", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with stage 4 or 5 on the CKD classification.\n\n          -  Of the patients that wants a living-donor kidney transplant of ABO blood type\n             compatible, patients with positive FCXM-T and negative CDC-T to the donor.\n\n          -  Patients with positive FCXM-T after performing twice DFPP therapy\n\n        Exclusion Criteria:\n\n          -  Patients who had taking to continue immunosuppressive drugs or steroids within 4\n             weeks before obtaining informed consent.\n\n          -  Patients who had IVIG therapy, or plasmapheresis therapy within 12 weeks before to\n             informed consent.\n\n          -  Patients who had Rituximab within 6 month before to informed consent.\n\n          -  Patients who have undergone splenectomy.\n\n          -  Patients with severe hepatic disorder or severe heart disorder.\n\n          -  Patients with receiving treatment of malignancy.\n\n          -  Patients with high risk of thromboembolism.\n\n          -  Patients with history of shock or hypersensitivity to GB-0998.\n\n          -  Patients with hereditary fructose intolerance or IgA deficiency.\n\n          -  Patients with pregnant or probably pregnant."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02032095", 
            "org_study_id": "B211-10"
        }, 
        "intervention": {
            "arm_group_label": "GB-0998", 
            "intervention_name": "GB-0998", 
            "intervention_type": "Drug", 
            "other_name": "Intravenous immunoglobulin (Venoglobulin IH)"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Immunoglobulins", 
                "Immunoglobulins, Intravenous", 
                "Rho(D) Immune Globulin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "IVIG", 
            "Renal transplantation", 
            "desensitization"
        ], 
        "lastchanged_date": "January 9, 2014", 
        "location": {
            "contact": {
                "email": "c-development@jbpo.or.jp", 
                "last_name": "HIroyuki Ishikawa"
            }, 
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan"
                }, 
                "name": "Japan Blood Products Organization"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.", 
        "overall_contact": {
            "email": "c-development@jbpo.or.jp", 
            "last_name": "Hiroyuki Ishikawa"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Negative rate of FCXM-T after the fourth administration of GB-0998", 
            "safety_issue": "Yes", 
            "time_frame": "at 4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02032095"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Japan Blood Products Organization", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Japan Blood Products Organization", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}